demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
ruxolitinib Cao

2 studies excluded by filtering options 0

6490 Kaplanski, 2020 0300selection pending
6714 DEVENT, 0 110risk of bias not avaialble